Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 123-128

  Shinden, Yoshiaki ^a,c   Akiyoshi, Sayuri ^b   Ueo, Hiroki ^a   Nambara, Syo ^a   Saito, Tomoko ^a   Komatsu, Hisateru ^a   Ueda, Masami ^a   Hirata, Hidenari ^a   Sakimura, Shotaro ^a   Uchi, Ryutaro ^a   Takano, Yuki ^a   Iguchi, Tomohiro ^a   Eguchi, Hidetoshi ^a   Sugimachi, Keishi ^a   Kijima, Yuko ^c   Ueo, Hiroaki ^d   Natsugoe, Shoji ^c   Mimori, Koshi ^a  

^a KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d Ueo Breast Surgery Hospital   (Japan)

Author keywords

Breast cancer; MiR 15a; Prognosis

Indexed keywords

MICRORNA 15A; TUMOR MARKER; MICRORNA; MIRN15 MICRORNA, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; BREAST TUMOR; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920460491     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Serpico D, Molino L and Di Cosimo S: microRNAs in breast cancer development and treatment. Cancer Treat Rev 40: 595-604, 2014.
2. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
3. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M and Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
4. Dong C, Ji M and Ji C: microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther 8: 200-205, 2009.
5. Tivnan A and McDonald KL: Current progress for the use of miRNAs in glioblastoma treatment. Mol Neurobiol 48: 757-768, 2013.
6. Tang J, Ahmad A and Sarkar FH: The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. International journal of molecular sciences 13: 13414-13437, 2012.
7. Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, Huang Y and Fang L: MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol 43: 1212-1218, 2013.
8. Liu X, Gu X, Sun L, Flowers AB, Rademaker AW, Zhou Y and Kiyokawa H: Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis. BMC cancer 14: 57, 2014.
9. Ota D, Mimori K, Yokobori T, Iwatsuki M, Kataoka A, Masuda N, Ishii H, Ohno S and Mori M: Identification of recurrencerelated microRNAs in the bone marrow of breast cancer patients. Int J Oncol 38: 955-962, 2011.
10. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS and Ditzel HJ: Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive earlystage breast cancer: A case control study. Mol Oncol 8: 874-883, 2014.
11. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ and Panel M: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology: official journal of the European Society for Medical Oncology/ ESMO 24: 2206-2223, 2013.
12. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO and Perou CM: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31: 203-209, 2013.